High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance

被引:6
|
作者
Peters, L. [1 ]
Mocroft, A. [2 ]
Soriano, V. [3 ]
Rockstroh, J. K. [4 ]
Kirkby, N. [5 ]
Reiss, P. [6 ]
Katlama, C. [7 ]
Zakharova, N. [8 ]
Flisiak, R. [9 ]
Lundgren, J. D. [1 ]
机构
[1] Univ Copenhagen, Rigshosp, Sect 2100, CHIP Dept Infect Dis & Rheumatol, DK-2100 Copenhagen O, Denmark
[2] Univ Coll Med Sch, London, England
[3] Hosp Carlos III, Dept Infect Dis, Madrid, Spain
[4] Univ Bonn, Bonn, Germany
[5] Rigshosp, Dept Clin Microbiol, DK-2100 Copenhagen, Denmark
[6] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[7] Hop La Pitie Salpetriere, Paris, France
[8] St Petersburg AIDS Ctr, St Petersburg, Russia
[9] Med Univ Bialystok, Dept Infect Dis, Bialystok, Poland
关键词
HCV; HCV RNA recurrence; HIV; injection drug use; INJECTION-DRUG USERS; REINFECTION; REACTIVATION; RISK;
D O I
10.1111/hiv.12160
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
ObjectivesFollowing resolution of hepatitis C virus (HCV) infection, recurrence has been shown to occur in some persons with repeated exposure to HCV. We aimed to investigate the rate and factors associated with HCV RNA recurrence among HIV-1-infected patients with prior spontaneous HCV RNA clearance in the EuroSIDA cohort. MethodsAll HIV-infected patients with documented prior spontaneous HCV clearance, and at least one subsequently collected plasma sample, were examined. The last sample was tested for HCV RNA and those with HCV RNA 615IU/mL were defined as having HCV recurrence and their characteristics were compared with those of patients who were still aviraemic. Logistic regression was used to identify factors associated with HCV recurrence. ResultsOf 191 eligible patients, 35 [18.3%; 95% confidence interval (CI) 12.8-23.8%] had HCV recurrence. Thirty-three (94.3%) were injecting drug users (IDUs). The median time between the first and last samples was 3.6 years (interquartile range 2.0-5.8 years). After adjustment, those on combination antiretroviral therapy [odds ratio (OR) 0.44; 95% CI 0.20-0.99; P=0.046] and older persons (OR 0.51 per 10 years older; 95% CI 0.28-0.95; P=0.033) were less likely to have HCV RNA recurrence, whereas IDUs were over 6 times more likely to have HCV RNA recurrence compared with non-IDUs (OR 6.58; 95% CI 1.48-29.28; P=0.013). ConclusionsAround 1 in 5 HIV-infected patients with prior spontaneous HCV RNA clearance had detectable HCV RNA during follow-up. Our findings underline the importance of maintaining focus on preventive measures to reduce IDU and sharing of contaminated needles. Clinicians should maintain a high degree of vigilance to identify patients with new HCV infection early.
引用
收藏
页码:615 / 620
页数:6
相关论文
共 50 条
  • [21] Increased rate of spontaneous clearance of hepatitis C virus in patients infected with HIV
    Dumitru, Irina Magdalena
    Rugina, Sorin
    Alexandrescu, Luana
    Dumitru, Eugen
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2014, 23 (04) : 461 - 462
  • [22] Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients
    Soriano, V
    Pérez-Olmeda, M
    Ríos, P
    Núñez, M
    García-Samaniego, J
    González-Lahoz, J
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (04) : 351 - 353
  • [23] Repeated HCV-clearance in an HIV-infected patient
    Vogel, M.
    Wasmuth, J-C.
    Rockstroh, J. K.
    Holm, S.
    Kuhlmann, B.
    INFECTION, 2007, 35 (02) : 120 - 121
  • [24] Repeated HCV-Clearance in an HIV-Infected Patient
    M. Vogel
    J.-C. Wasmuth
    J. K. Rockstroh
    S. Holm
    B. Kuhlmann
    Infection, 2007, 35
  • [25] Comparison of serum virus load among individuals infected with hepatitis C virus (HCV) by Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assay.
    Olaso, V
    Cordoba, J
    Lopez, B
    Lainez, B
    Arguello, L
    Eslamdoost, N
    Gobernado, M
    Berenguer, J
    HEPATOLOGY, 1997, 26 (04) : 1789 - 1789
  • [26] Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes
    Agwale, SM
    Tanimoto, L
    Womack, C
    Odama, L
    Leung, K
    Duey, D
    Negedu-Momoh, R
    Audu, I
    Mohammed, SB
    Inyang, U
    Graham, B
    Ziermann, R
    JOURNAL OF CLINICAL VIROLOGY, 2004, 31 : S3 - S6
  • [27] Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal
    KC, Sudhamshu
    Murphy, Holly
    Dixit, Sameer
    Rai, Apurva
    Pradhan, Bickram
    Lagrange-Xelot, Marie
    Karki, Niyanta
    Dureault, Amelie
    Karmacharya, Ujjwal
    Panthi, Santosh
    Tulachan, Nabin
    KC, Prawchan
    KC, Anjay
    Rajbhandari, Rajesh
    Trotter, Andrew B.
    Goelz, Joerg
    Pradat, Pierre
    Trepo, Christian
    Creac'H, Philippe
    PLOS NEGLECTED TROPICAL DISEASES, 2020, 14 (12): : e0008931
  • [28] HEPATITIS C (HCV) THERAPY FOR HCV MONO-INFECTED AND HIV-HCV CO-INFECTED INDIVIDUALS LIVING IN NEPAL
    Kc, Sudhamshu
    Murphy, Holly
    Dixit, Sameer
    Rai, Apurva
    Pradhan, Bickram
    Lagrange-Xelot, Marie
    Karki, Niyanta
    Dureault, Amelie
    Karmacharya, Ujjwal
    Panti, Santosh
    Tulachan, Nabin
    Kc, Prawchan
    Kc, Anjay
    Rajbhandari, Rajesh
    Trotter, Andrew
    Goelz, Joerg
    Pradat, Pierre
    Trepo, Christian
    Creac'H, Philippe
    HEPATOLOGY, 2019, 70 : 963A - 964A
  • [29] Impact of hepatitis C virus (HCV) on morbidity and mortality rates among HIV-infected patients
    Núnez, M
    Martín-Carbonero, L
    Soriano, V
    CLINICAL INFECTIOUS DISEASES, 2003, 37 (03) : 460 - 461
  • [30] High serum hepatitis C virus (HCV) RNA load predicts the presence of HCV RNA in saliva from individuals with chronic and acute HCV infection
    Wang, CC
    Morishima, C
    Chung, MJ
    Engelberg, R
    Krantz, E
    Krows, M
    Sullivan, DG
    Gretch, DR
    Corey, L
    JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (05): : 672 - 676